|
|||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||
Office Based Opioid Treatment Basic Information for Physicians About Buprenorphine Federal Law Code of Federal Regulations. Confidentiality of Alcohol and Drug Abuse Patient Records. 42 CRF Part 2. Read PDF File Document. Public Law 106-310, 106th Congress. Sec. 3502. Controlled Substances Act, October 17, 2000. Full Law Basic Information About DATA:On October 17, 2000…
Policy Statement Number 1 April 1994 The National Alliance of Methadone Advocates supports the concept of Medical Maintenance and the prescribing of methadone outside of the methadone clinic setting. Medical Maintenance was initially implemented for patients who had achieved a high level of functionally in society and were hindered by the regulations that were conceived…
Nominations Open for the 2022 Richard Lane/Robert Holden Advocacy Award! NAMA Recovery AATOD Lane Holden Award May 1, 2022 | 0 Richard Lane was a long-term heroin user who, upon release from prison in 1967, was instrumental in establishing one of the Nation’s first opioid treatment programs. In 1974, he became the Executive…
Send To: National Alliance of Methadone Advocates Inc. Back To NAMA Home Page NAMA Membership Office 435 Second Avenue New York, NY 11000 Membership Application Name: _______________________________________________________ Organization: ________________________________________________________________________ Title: ________________________________________________________ Degree(s):__________________________ Address: ________________________________________________________________________ Address: ________________________________________________________________________ City: _____________________________________ State: ______Postal Code: ________Country: ___ Home Phone: (___)__________________________ Work Phone: (___)______________________ Alternate Phone:(___)________________________Fax: (___)______________________________ Email:______________________________________ If you have email may we send you…
Issues To Focus On LAAM Manufacture to Be Discontinued August 23, 2003 Washington, D.C. Roxanne the manufacturer of LAAM has informed the FDA that manufacture of the medication is being discontinued. Distribution will continue until the inventory is depleted. Roxanne estimates this to be in early January 2004. The reason for the action is the…
Join Together Online January 21, 2003 While 616 physicians nationwide are now authorized to prescribe buprenorphine, its widespread use is still an issue, the Baltimore Sun reported on January 15. Product availability is the first problem. Despite receiving FDA approval in October, the manufacturer did not ship the product to pharmaceutical warehouses until last week….